Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party

被引：14

作者：

Horstmann, K. ^{[1
,2
]}

Boumendil, A. ^{[1
]}

Finke, J. ^{[3
]}

Finel, H. ^{[1
]}

Kanfer, E. ^{[4
]}

Milone, G. ^{[5
]}

Russell, N. ^{[6
]}

Bacigalupo, A. ^{[7
]}

Chalandon, Y. ^{[8
,9
]}

Diez-Martin, J. L. ^{[10
]}

Ifrah, N. ^{[11
]}

Jurado Chacon, M. ^{[2
,12
]}

Dreger, P. ^{[1
,2
]}

机构：

[1] EBMT Lymphoma Working Party, Paris, France

[2] Heidelberg Univ, Dept Med 5, D-69120 Heidelberg, Germany

[3] Univ Freiburg, Dept Med 1, D-79106 Freiburg, Germany

[4] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, London, England

[5] Azienda Osped Policlin Vittorio Emanuele, Programma Trapianto Emopoiet, Catania, Italy

[6] Univ Nottingham Hosp, Ctr Clin Hematol, Nottingham NG7 2UH, England

[7] IRCCS San Martino, Div Hematol & Bone Marrow Transplantat, Genoa, Italy

[8] Univ Hosp Geneva, Div Hematol, Dept Med Specialties, Geneva, Switzerland

[9] Univ Geneva, Fac Med, Geneva, Switzerland

[10] HGU Gregorio Maranon, Dept Hematol & Hemotherapy, Madrid, Spain

[11] CHRU, Serv Malad Sang, Angers, France

[12] Hosp Univ Virgen Ias Nieves, Granada, Spain

来源：

BONE MARROW TRANSPLANTATION | 2015年 / 50卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; EUROPEAN GROUP; MARROW-TRANSPLANTATION; SOCIETE-FRANCAISE; ACUTE-LEUKEMIA; RISK; STRATEGY; BLOOD; INFUSIONS; SURVIVAL;

D O I：

10.1038/bmt.2015.12

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with lymphoma who had relapsed after a first allogeneic transplant (alloHSCT_1). Patients >= 18 years who had received an alloHSCT_2 for lymphoma relapse between 2000 and 2011 were eligible. One hundred and forty patients were identified. The diagnosis was Hodgkin lymphoma (HL) in 31%, diffuse large B-cell lymphoma in 14%, T-cell lymphoma in 12%, indolent lymphoma in 19%, mantle cell lymphoma in 16% and other lymphomas in 8% of the patients. The median interval from alloHSCT_1 to alloHSCT_2 was 19 (range 4-116) months. Disease status at alloHSCT_2 was chemosensitive in 46%, refractory in 43% and unknown in 11% of the patients. Three-year PFS, OS, relapse incidence and nonrelapse mortality were 19%, 29%, 58% and 23%, respectively. PFS and OS were significantly affected by refractory disease at alloHSCT_2 and a short interval between alloHSCT_1 and alloHSCT_2. Long-term PFS was observed across all lymphoma subsets except for aggressive B-cell lymphoma. In conclusion, alloHSCT_2 is feasible and can result in long-term disease control in patients with lymphoma recurrence after alloHSCT_1, in particular if relapse occurs late and is chemosensitive.

引用

页码：790 / 794

页数：5

共 50 条

[41] AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE RITUXIMAB ERA: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY
Avivi, I.
Boumendil, A.
Finel, H.
Nagler, A.
De Souza, C.
Unal, A.
Botelho de Sousa, A.
Ribera Santasusana, J. M.
Vandenberghe, E.
Afanasyev, B.
Bordessoule, D.
Moraleda, J. M.
Conde, E.
Pohlreich, D.
Dreger, P.
BONE MARROW TRANSPLANTATION, 2014, 49 : S60 - S61
[42] Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party
Avivi, Irit
Boumendil, Ariane
Finel, Herve Herve
Nagler, Arnon
Bothello, Aida Sousa
Ribera Santasusana, Josep Maria
Vandenberghe, Elisabeth A.
Afanasyev, Boris
Bordessoule, Dominique
Maria Moraleda, Jose
Conde, Eulogio
Pohlreich, David
Dreger, Peter
BLOOD, 2014, 124 (21)
[43] Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party
Kai Hübel
Alessandro Re
Ariane Boumendil
Herve Finel
Marcus Hentrich
Stephen Robinson
Christoph Wyen
Mariagrazia Michieli
Edward Kanfer
Jose Luis Diez-Martin
Pascual Balsalobre
Laure Vincent
Wilfried Schroyens
Josep Maria Ribera Santasusana
Nicolaus Kröger
Xaver Schiel
Kate Cwynarski
Albert Esquirol
Aida Botelho Sousa
Chiara Cattaneo
Silvia Montoto
Peter Dreger
Bone Marrow Transplantation, 2019, 54 : 1625 - 1631
[44] Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party
Huebl, Kai
Re, Alessandro
Boumendil, Ariane
Finel, Herve
Hentrich, Marcus
Robinson, Stephen
Wyen, Christoph
Michieli, Mariagrazia
Kanfer, Edward
Diez-Martin, Jose Luis
Balsalobre, Pascual
Vincent, Laure
Schroyens, Wilfried
Ribera Santasusana, Josep Maria
Kroeger, Nicolaus
Schiel, Xaver
Cwynarski, Kate
Esquirol, Albert
Sousa, Aida Botelho
Cattaneo, Chiara
Montoto, Silvia
Dreger, Peter
BONE MARROW TRANSPLANTATION, 2019, 54 (10) : 1625 - 1631
[45] AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT) IS HIGHLY EFFECTIVE IN RELAPSED NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL): A RETROSPECTIVE STUDY BY THE EBMT LYMPHOMA WORKING PARTY
Akhtar, S.
Boumendil, A.
Finel, H.
Masszi, T.
Jindra, P.
Nemet, D.
Baurmann, H.
Begiun, Y.
Castagna, L.
Ferrara, F.
Foa, R.
Malladi, R.
Moraleda, J. M.
Bloor, A.
Salles, G.
Meissner, J.
Sureda, A.
Dreger, P.
HAEMATOLOGICA, 2016, 101 : 101 - 101
[46] Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Follicular Lymphoma: A Combined Analysis on Behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR
Sureda, Anna
Zhang, Mei-Jie
Dreger, Peter
Carreras, Jeanette
Fenske, Timothy
Finel, Herve
Schouten, Harry
Montoto, Silvia
Robinson, Stephen
Smith, Sonali M.
Boumedil, Ariane
Hamadani, Mehdi
Pasquini, Marcelo C.
CANCER, 2018, 124 (08) : 1733 - 1742
[47] UNRELATED DONOR (UD) ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) IN PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA (AML): REPORT OF 381 PATIENTS FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
Brissot, E.
Labopin, M.
Stelljes, M.
Ehninger, G.
Schwerdtfeger, R.
Zander, A. R.
Mielke, S.
Ganser, A.
Finke, J.
Schufer-Eckart, K.
Bunjes, D.
Kroeger, N.
Schmid, C.
Bethge, W. A.
Kolb, H. J.
Blau, I. W.
Vitek, A.
Bochtler, T.
Meyer, R. G.
Holler, E.
Esteve, J.
Nagler, A.
Mohty, M.
HAEMATOLOGICA, 2015, 100 : 13 - 14
[48] Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT
Bento, Leyre
Boumendil, Ariane
Finel, Herve
Khvedelidze, Irma
Blaise, Didier
Fegueux, Nathalie
Castagna, Luca
Forcade, Edouard
Chevallier, Patrice
Mordini, Nicola
Brice, Pauline
Deconinck, Eric
Gramatzki, Martin
Corradini, Paolo
Hunault, Mathilde
Musso, Maurizio
Tsoulkani, Anna
Caballero, Dolores
Nati, Sandro
Montoto, Silvia
Sureda, Anna
BONE MARROW TRANSPLANTATION, 2021, 56 (03) : 655 - 663
[49] Outcomes of second allogeneic hematopoietic stem cell Transplantation (Allo-SCT) in patients with acute lymphoblastic leukemia (ALL)
Al Malki, Monzr M.
Aldoss, Ibrahim
Forman, Stephen J.
Stiller, Tracey
Pullarkat, Vinod A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S175 - S175
[50] Solid organ transplantation after allogeneic stem cell transplantation: a retrospective study of the Chronic Leukaemia Working Party of the EBMT
Koenecke, C.
Hertenstein, B.
van Biezen, A.
Dammann, E.
Niederwieser, D.
de Witte, T.
Ruutu, T.
BONE MARROW TRANSPLANTATION, 2008, 41 : S2 - S2

← 1 2 3 4 5 →